Saturday, May 18, 2013
"Concise industry news from the US pharmaceutical industry..."
Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Blog
Spencer Green
Chairman, GDS International
Chairman, GDS International
Sales and the 'Talent Magnet'
A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?26 May 2011
White Papers
Focus Areas
Cover Stories
Could open innovation save the pharmaceuti...
The pharmaceutical industry desperately needs to evolve in order to survive. Is open innovation the answer?
Vendor Perspectives
-
No free lunch
There is a gross misconception that once study sites are selected, patients should be readily available for the clinical trial and at no cost. No other industry operates...Read more -
Communication platforms - The right meth...
In this fast-moving, information-rich society where people must stay connected almost constantly, technology has certainly risen to meet that demand. We now have a...Read more -
Clinical imaging solutions
Affiliated with the American College of Radiology® (ACR®), ACR Image Metrix™ is an imaging contract research organization (CRO) that improves the efficiency of drug and...Read more -
Problem solved: rapid sample transfer be...
Multichannel pipettes have become an indispensable liquid handling tool for biochemical and molecular biology assays in life science laboratories over the last decades....Read more -
New commercial models for new market rea...
Maximizing the efficiency of commercial operations is standard fare for companies operating in a difficult economy and with budget constraints.Read more -
Biomarker discovery via monoclonal antib...
A Biochip Protein Profiling Array, utilising monoclonal antibody (mAB) libraries generated against the natural human plasma proteome.Read more
Industry Analysts
-
Eli Lilly and Company's transformation
How Eli Lilly and Company’s transformation towards a networking structure could serve it well at the innovation table.Read more -
Facilitating continuous improvement
Amid increasing interest by pharmaceutical manufacturers and regulatory bodies to apply quality by design (QbD) principles to processes and product, organisations are...Read more -
Pharma steps towards the emerging markets
Frost & Sullivan’s Sumit Sharma on the importance of emerging markets to the future success of the pharma industry.Read more -
Fred Hassan: Becoming an exceptional leade...
Fred Hassan opens up on what it takes to be an exceptional leader in the pharmaceutical industry.Read more -
Can digital pathology save pharmaceutical ...
Let’s start with what we know. For years, the state of pharmaceutical drug development has been in decline in terms of new molecular entities or biologics that are clearing...Read more -
Eradicating meningococcal
NGP talks to Rino Rappuoli of Novartis about the breakthrough vaccines that could consign five deadly types of meningococcal disease to history.Read more
Executive Interviews
Centralized cardiac safety
How to achieve improved science at a lower cost with the most stakeholder convenience.
Read more
Stereology going mainstream
Lars Peterson discusses how whole slide stereology is beginning to make an impact in the biopharmaceutical industry.
Read more
Protein-based therapeutic manufacturing
Robert J. Broeze is Chief Commercial Officer at Laureate Pharma. He talks to Next Generation Pharmaceutical about manufacturing therapeutic proteins.
Read more
Next Generation Healthcare Summit
25th - 27th October 2010
As healthcare costs continue to rise, health providers around the country feel a sharp sense of urgency in deploying information technology to lower costs, reduce medical errors, enhance outcomes, and spur efficiency in an industry known for legendary inefficiency.
Source: www.ngpharma.com© 2013 GDS Publishing Ltd. All rights reserved.